Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP

Two Sigma Investments LP boosted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 226.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,664 shares of the company's stock after buying an additional 23,342 shares during the period. Two Sigma Investments LP owned 0.08% of Keros Therapeutics worth $533,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KROS. Barclays PLC grew its position in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Handelsbanken Fonder AB boosted its position in shares of Keros Therapeutics by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after purchasing an additional 1,100 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its position in shares of Keros Therapeutics by 1,910.2% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 74,255 shares of the company's stock valued at $1,175,000 after purchasing an additional 70,561 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Keros Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 97,878 shares of the company's stock valued at $1,549,000 after purchasing an additional 2,462 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Keros Therapeutics by 7.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 279,682 shares of the company's stock valued at $4,427,000 after purchasing an additional 19,562 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Insider Transactions at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This represents a 27.01% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KROS. HC Wainwright reduced their price objective on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wedbush restated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Friday, May 30th. Truist Financial reduced their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Finally, Scotiabank reduced their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $37.00.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $15.04 on Monday. The company has a 50 day simple moving average of $13.44 and a 200-day simple moving average of $17.76. The firm has a market capitalization of $610.85 million, a price-to-earnings ratio of -2.89 and a beta of 1.31. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period in the prior year, the firm earned ($1.21) earnings per share. On average, analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.